Literature DB >> 8016901

Self-selection for mammography and breast cancer incidence by stage.

L Bucchi1, M Serafini, O Nanni, G Buzzi, N Morini, C Naldoni, P Schincaglia.   

Abstract

AIMS AND
BACKGROUND: In the field of breast cancer control, obtaining population-based data on spontaneous mammography (MG) screening should be a priority. This study focuses on the breast cancer incidence and stage distribution in relation to MG use in Ravenna (Italy), 1987-88.
METHODS: We estimated the MG rates, expected (E) incidence based on mortality data, observed (O) incidence, predicted excess incidence based on MG rates, observed excess incidence, and stage distribution according to the MG history.
RESULTS: The highest MG rate (37%) was found among residents aged 40-44 but none of these had a T1a-bNO breast cancer diagnosed nor was the predicted excess incidence demonstrated. Between 45 and 64 years, 80% of self-selected screenees had repeat ("incidence") MG and the O:E incidence ratio was 1.32 (95% CI 1.09-1.58). The observed excess incidence was 3.8-fold (95% CI 2.56-5.16) greater than that predicted. Advanced (T2+ and/or N1+) cases accounted for 42% of patients diagnosed within 3 years of their last MG, for 55% of those diagnosed more than 3 years after their last MG, and for 70% of those with no previous MG. Above age 70, a significant worsening of stage at diagnosis was associated with a clearcut drop self-referral for MG.
CONCLUSIONS: The results indicate that self-selection and its implications are major features of spontaneous screening practice.

Entities:  

Mesh:

Year:  1994        PMID: 8016901     DOI: 10.1177/030089169408000206

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  1 in total

1.  Incidence, detection, and tumour stage of breast cancer in a cohort of Italian women with negative screening mammography report recommending early (short-interval) rescreen.

Authors:  Alessandra Ravaioli; Flavia Foca; Americo Colamartini; Fabio Falcini; Carlo Naldoni; Alba C Finarelli; Priscilla Sassoli de Bianchi; Lauro Bucchi
Journal:  BMC Med       Date:  2010-02-01       Impact factor: 8.775

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.